Stomach Cancer Treatment Market Size
Global Stomach Cancer Treatment Market reached US$ 6.86 billion in 2025 and is expected to reach US$ 18.60 billion by 2033 growing with a CAGR of 13.4% during the forecast period 2026-2033.
Stomach cancer is a disease in which malignant (cancer) cells are formed in the stomach lining. Stomach cancer usually begins in the mucus-producing cells that line the stomach. Symptoms of stomach cancer include indigestion and stomach discomfort or pain. Most people typically do not show signs in the earlier stages due to which diagnosis becomes difficult. Because of this, it often goes undiagnosed until after it spreads to other body parts and cause metastasis.
Gastric cancer is the third leading cause of death throughout the world. According to the National Cancer Institute, 1.8% of the deaths caused by cancer are due to stomach cancer. According to the American Cancer Society estimate in 2022, stomach cancer accounts for about 1.5% of all new cancers in the U.S. annually.
Furthermore, the rising incidence of gastric cancer, the adoption of a sedentary lifestyle and irregular food habits, and rising research and development in the oncology sector are a few factors that are expected to drive the market in the forthcoming period.
Stomach Cancer Treatment Market Scope
| Metrics | Details |
| CAGR | 13.4% |
| Size Available for Years | 2025-2033 |
| Forecast Period | 2026-2033 |
| Data Availability | Value (US$) |
| Segments Covered | Cancer Type, Treatment Type, Distribution Channel, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For More Inisights about the Market Request free Sample
Stomach Cancer Treatment Market Dynamics
Increasing Product Launches
Gastric cancer is currently the fifth most frequently diagnosed cancer and the fourth leading cancer-related cause of death worldwide. Over 90-95% of cases are classified as adenocarcinoma. The American Cancer Society’s 2022 estimates include 26,380 new cases and 11,090 deaths from gastric cancer.
For instance, in February 2023, Enhertu launched gastric cancer tertiary treatment in South Korea. The first and only HER2 target ADC, which improves treatment for advanced and metastatic gastric cancer.
Additionally, in April 2023, HUTCHMED (China) Limited was granted a New Drug Application (“NDA”) for fruquintinib along with paclitaxel for the treatment of second-line progressive gastric or gastroesophageal junction adenocarcinoma in China was accepted for consideration by the China National Medical Products Administration (“NMPA”).
Increasing Drug Pipeline
Various biotech and pharmaceutical companies are developing various drugs which are in the pipeline. Companies like CNBG-Virogin Biotech, Minneamrita Therapeutics LLC, etc. These drugs are tested for safety and efficacy in treating gastric cancer. Combination drugs are given to the patients to observe the effectiveness of the therapy.
Zhejiang Cancer Hospital along with CSPC Ouyi Pharmaceutical Co., Ltd. are conducting a phase 3 clinical trial to compare the efficacy and safety of Albumin-bound Paclitaxel plus S-1 versus Oxaliplatin plus capecitabine (XELOX) treating stage 3 gastric cancer as adjuvant setting. The estimated completion date is October 31, 2024.
Complications Related to Radiotherapy and Chemotherapy
Chemotherapy and radiotherapy are the leading treatments for stomach cancer. Chemotherapy may also lead to implications such as sunlight sensitivity and increasing sunburn risk. Chemotherapy can cause individuals to become temporarily lactose intolerant. Both chemotherapy and radiation therapy for stomach cancer can cause diarrhea, nausea, and vomiting. Radiation toward the pelvis and some chemotherapy drugs lead to urinary tract infections (UTIs). Apart from treating stomach cancer, it can decrease estrogen levels, causing symptoms like vaginal dryness and conditions like primary ovarian insufficiency, testosterone levels, and sperm count.
Stomach Cancer Treatment Market Segment Analysis
The global stomach cancer treatment market is segmented based on cancer type, treatment type, end-user, and region.
The Chemotherapy Segment Accounted for Approximately XX% of the Market Share
Chemotherapy can target cancer cells that have spread beyond the stomach or shrink the tumor before surgery and alleviate symptoms in advanced cases of gastric cancer. The use of chemotherapy in gastric cancer is rapidly evolving, and the optimal treatment strategy may vary depending on the tumor's molecular characteristics, the stage of cancer, and other individual factors.
Due to the increased use of chemotherapy treatment for stomach cancer, there is an increase in chemotherapeutic products in the market. For instance, in April 2022, BDR Pharmaceuticals launched Furmecil, a generic oral drug for treating advanced gastric cancer.
Furthermore, in June 2023, Merck & Co.’s Keytruda, in a new phase 3 trial, Keytruda plus chemotherapy, significantly extended patients’ lives over chemo alone in newly diagnosed HER2-negative gastric or gastroesophageal junction cancers that are advanced or metastatic. The Keytruda combination cut the risk of death by 22%.
Stomach Cancer Treatment Market Geographical Share
North America accounted for Approximately XX% of the Market Share in 2022
North America accounts for the largest market share for stomach cancer treatment. The American Cancer Society's estimates for stomach cancer (also known as gastric cancer) in the United States for 2023 are about 26,500 new cases of stomach cancer (15,930 in men and 10,570 in women).
In addition to that, lifestyle factors such as improper diet and smoking cause gastric cancer. Diets high in salt, smoked or pickled foods, and low in fruits and vegetables have been linked to an increase in the risk of gastric cancer. Similarly, smoking is a most common risk factor for gastric cancer and the prevalence of smoking in many countries in North America remains high. All these factors are anticipated to boost the growth of the North American gastric cancer market during the forecast period.
Recent Developments – Stomach Cancer Treatment Market
- February 2026: Across North America, Europe, and Asia Pacific, increasing adoption of immunotherapy and targeted therapy significantly accelerated market growth, driven by rising gastric cancer incidence and demand for personalized treatment approaches.
- January 2026: Advancements in precision oncology, including HER2-targeted therapies, kinase inhibitors, and biomarker-based treatments, enabled improved patient outcomes and more effective treatment selection.
- December 2025: Leading companies such as F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Pfizer Inc., AstraZeneca PLC, and Eli Lilly and Company expanded oncology pipelines, strengthened clinical trials, and increased investments in advanced gastric cancer therapies.
- November 2025: Increasing adoption of immune checkpoint inhibitors and combination therapies improved survival rates and became a key trend in advanced and metastatic gastric cancer treatment.
- October 2025: Regulatory advancements and approvals, including expanded indications for immunotherapy drugs such as Imfinzi, enhanced treatment options and accelerated market expansion.
- September 2025: In the United States and Europe, strong R&D investments, increasing clinical trials, and favorable regulatory frameworks significantly supported innovation in gastric cancer treatment solutions.
- August 2025: In Asia Pacific, particularly in China, Japan, and India, rising disease prevalence and growing adoption of advanced therapies accelerated regional market growth.
- July 2025: Continuous innovation in combination therapies, antibody-drug conjugates, and immuno-oncology, along with increasing collaborations between pharmaceutical companies and research institutes, supported long-term global growth of the stomach cancer treatment market.
Stomach Cancer Treatment Market Companies
The major global players in the stomach cancer treatment market include Merck & Co., Inc, Bristol-Myers Squibb, Accord Healthcare, Sanofi S.A, Bayer Pharma AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Celltrion, Inc., Genentech, Inc., and Winthrop US among others.
Why Purchase the Report?
- To visualize the global stomach cancer treatment market segmentation based on cancer type, treatment type, end user, and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of stomach cancer treatment market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global stomach cancer treatment market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Target Audience
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
